Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-of-Concept Clinical Trial
Open Access
- 2 May 2012
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 91 (6), 975-985
- https://doi.org/10.1038/clpt.2011.370
Abstract
The orexin system is a key regulator of sleep and wakefulness. In a multicenter, double‐blind, randomized, placebo‐controlled, two‐way crossover study, 161 primary insomnia patients received either the dual orexin receptor antagonist almorexant, at 400, 200, 100, or 50 mg in consecutive stages, or placebo on treatment nights at 1‐week intervals. The primary end point was sleep efficiency (SE) measured by polysomnography; secondary end points were objective latency to persistent sleep (LPS), wake after sleep onset (WASO), safety, and tolerability. Dose‐dependent almorexant effects were observed on SE, LPS, and WASO. SE improved significantly after almorexant 400 mg vs. placebo (mean treatment effect 14.4%; P < 0.001). LPS (–18 min (P = 0.02)) and WASO (–54 min (P < 0.001)) decreased significantly at 400 mg vs. placebo. Adverse‐event incidence was dose‐related. Almorexant consistently and dose‐dependently improved sleep variables. The orexin system may offer a new treatment approach for primary insomnia. Clinical Pharmacology & Therapeutics (2012); 91 6, 975–985. doi:10.1038/clpt.2011.370Keywords
This publication has 58 references indexed in Scilit:
- Orexin/Hypocretin and Histamine: Distinct Roles in the Control of Wakefulness Demonstrated Using Knock-Out Mouse ModelsJournal of Neuroscience, 2009
- Algorithms for the assessment and management of insomnia in primary carePatient Preference and Adherence, 2009
- The Efficacy and Safety of Drug Treatments for Chronic Insomnia in Adults: A Meta-analysis of RCTsJournal of General Internal Medicine, 2007
- Update on the Safety Considerations in the Management of Insomnia With HypnoticsThe Primary Care Companion For CNS Disorders, 2007
- Discharge of Identified Orexin/Hypocretin Neurons across the Sleep-Waking CycleJournal of Neuroscience, 2005
- The Role of Benzodiazepines in the Treatment of InsomniaJournal of the American Geriatrics Society, 2001
- Tolerance and rebound insomnia with rapidly eliminated hypnoticsInternational Clinical Psychopharmacology, 1999
- Estazolam and Flurazepam: A Multicenter, Placebo-Controlled Comparative Study in Outpatients with InsomniaThe Journal of Clinical Pharmacology, 1990
- Efficacy Without Tolerance or Rebound Insomnia for Midazolam and Temazepam After Use for One to Three MonthsThe Journal of Clinical Pharmacology, 1987
- A Rating Instrument For Anxiety DisordersPsychosomatics, 1971